Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 2/20 | 0.36 |
| ▸ | IL1B | P01584 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25834275 | 0.84 | CRBN (0.39) | CRBNDDB1ALDH1A1IKZF3CHRM2 | |
| SCHEMBL19370616 | 0.83 | CRBN (0.54) | CRBNDDB1ALDH1A1IKZF3CHRM2 | |
| SCHEMBL23292788 | 0.83 | CRBN (0.54) | CRBNDDB1ALDH1A1IKZF3CHRM2 | |
| SCHEMBL14985930 | 0.83 | CRBN (0.54) | CRBNDDB1ALDH1A1IKZF3CHRM2 | |
| SCHEMBL25834286 | 0.78 | L3MBTL1 (0.37) | CRBNDDB1ALDH1A1IKZF3CHRM2 | |
| SCHEMBL26846868 | 0.75 | ALDH1A1 (0.41) | CRBNDDB1ALDH1A1IKZF3CHRM2 | |
| SCHEMBL25834124 | 0.72 | ALDH1A1 (0.44) | CRBNDDB1ALDH1A1IKZF3CHRM2 | |
| SCHEMBL411456 | 0.72 | CRBN (0.71) | CRBNDDB1ALDH1A1IKZF3CHRM2 | |
| SCHEMBL29330443 | 0.69 | CRBN (0.56) | CRBNDDB1ALDH1A1IKZF3CHRM2 | |
| SCHEMBL20317524 | 0.69 | CRBN (0.61) | CRBNDDB1ALDH1A1IKZF3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | CRBN 2/4885DDB1 3336/4885ALDH1A1 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.